The U.S. Defense Health Agency awarded a $1,200,000 Project Grant to Baylor College of Medicine to support the research project "ELIMINATING BONE METASTASIS BY BONE-TARGETING E-CADHERIN ANTIBODY NANOGEL". The grant, provided under the Military Medical Research and Development (CFDA 12.420) program, will fund a 3-year research initiative from April 1, 2025 to March 31, 2028 aimed at developing a novel bone-targeting antibody nanogel therapy to eliminate bone metastasis. This federal grant supports Baylor College of Medicine's expertise in biomedical research, particularly in the areas of cancer, genomics, and innovative therapeutic approaches. The project seeks to advance treatments for a critical military health challenge, leveraging Baylor's capabilities as a leading academic medical institution to conduct this innovative, impactful research for the benefit of service members and the broader public.
Generated 2/25/25, 3:33 AM